REED ELIZABETH E 4

What Happened
Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics (TVTX), sold a total of 2,994 shares in two open‑market transactions on February 4, 2026. She sold 2,485 shares at an average reported price of $32.07 (proceeds $79,694) and 509 shares at an average reported price of $32.74 (proceeds $16,665), for combined proceeds of roughly $96,359. These were sales (not purchases) and appear to include shares sold to cover tax obligations from RSU vesting.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 5, 2026 (appears timely).
• Lots: 2,485 shares @ weighted avg $32.07 (price range $31.63–$32.61); 509 shares @ weighted avg $32.74 (price range $32.64–$32.90).
• Total shares sold: 2,994; total reported proceeds ≈ $96,359.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: Sale made pursuant to a written 10b5‑1 trading plan (adopted June 16, 2025) and includes shares sold to cover tax withholding from RSU vesting. Full breakdown of shares sold at each price is available upon request (per filing footnotes).
• Transaction type code: S = Sale.

Context
Sales executed under a 10b5‑1 plan are typically pre‑scheduled and can be used for routine needs (including tax withholding on vested awards); they do not by themselves indicate management sentiment about the company. For retail investors, purchases by insiders are often considered more informative about confidence than routine, plan‑driven sales.